Welcome to our dedicated page for Cardio Diagnostics Holdings news (Ticker: $CDIO), a resource for investors and traders seeking the latest updates and insights on Cardio Diagnostics Holdings stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cardio Diagnostics Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cardio Diagnostics Holdings's position in the market.
Cardio Diagnostics announced the publication of a study showing that its PrecisionCHD™ test could save health insurers over $113 million annually. The study demonstrated the potential economic benefits of the test for the detection and management of coronary heart disease, offering significant cost savings compared to traditional tests. PrecisionCHD is an AI-powered multiomic DNA test that evaluates six DNA methylation and ten genetic biomarkers, with a sensitivity and specificity of 79% and 76%, respectively. The budget impact model revealed estimated savings of $113.6 million per year for a plan with one million members, highlighting the test's cost efficiency and effectiveness.